BioSpace News Archive

Based on evaluation of all the FDA EUA approved kits before July 27, 2020, DiaCarta’s QuantiVirusTM SARS-CoV-2 Multiplex Test ranks among the top 10 kits in terms of low limit of detection (LoD). DiaCarta is the top 6 company, after Perkin Elmer, Roche, Quest, RTA and BD Biosciences.

Nobel Biocare USA is pleased to announce the appointment of Dr. Reena Gajjar as Vice President, Clinical & Professional Development. As a prosthodontist and entrepreneur, Dr. Gajjar has founded and scaled services, software and physical solutions in the dental, technology, education and aesthetic industries. S

In preclinical research, the approach successfully combines oncolytic virus and CAR T cell therapy

CenExel Centers of Excellence are participating in U.S. Operation Warp Speed projects to advance COVID-19 vaccine research quickly without sacrificing quality. The Centers are already supporting seven ongoing trials

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that Jounce management will participate in fireside chats at three upcoming investor conferences in September

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that the company will participate in the 2020 Wells Fargo Virtual Healthcare Conference in September.

OPKO Health, Inc. announced that management will be participating in two upcoming virtual investor conferences.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that its management team will present at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020.

Applied Genetic Technologies Corporation announced that it will provide a management update on its planned Phase 2/3 X-Linked Retinitis Pigmentosa clinical trial design, a re-analysis of dose Groups 2 and 4 data, and new preliminary visual sensitivity data from Group 5; data from Group 5 is in advance of the full interim data analysis that the Company expects to provide in 4Q 2020 for both Groups 5 and 6.

AEON Biopharma, Inc., a private biotechnology company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 injection, announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for ABP-450 to treat cervical dystonia.